Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Topotecan: Small Cell Lung Cancer (first-line) after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Topotecan Injection is a topoisomerase inhibitor indicated for treatment of small cell lung cancer (SCLC) platinum-sensitive disease in patients who progressed at least 60 days after initiation of first-line chemotherapy.

Broader topic: Small Cell Lung Cancer

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
first-line
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      after initiation of first-line chemotherapy
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Topotecan (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    Topotecan Injection is a topoisomerase inhibitor indicated for treatment of small cell lung cancer (SCLC) platinum-sensitive disease in patients who progressed at least 60 days after initiation of first-line chemotherapy.

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice